市場調查報告書
商品編碼
1408301
HIFU(高強度聚焦超音波)全球市場:規模、預測(2024-2030)、產業趨勢、份額、成長、考量、通貨膨脹的影響、公司分析High Intensity Focused Ultrasound (HIFU) Market, Size, Global Forecast 2024-2030, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis |
到 2030 年,全球 HIFU(高強度聚焦超音波)治療市場預計價值約 1.9418 億美元。 HIFU 使用特定的超音波瞄準特定組織並產生治療熱量,而不損害周圍區域。 與標準藥物相比,HIFU 廣泛用於治療前列腺癌和子宮肌瘤等疾病,可以最大限度地減少治癒和副作用。 HIFU 的聲譽源於其精確性、微創性以及在各個醫療領域的能力計劃。 隨著對非手術幹預的需求不斷增加,HIFU 因其有效性和對患者影響最小而成為一種利用臨床進展的變革性技術。
發展中國家的癌症發生率異常高,根據全球疾病負擔 (GBD),大約三分之一的人一生中都會受到影響。 子宮肌瘤影響 77% 的 50 歲女性,估計有 2.2605 億病例,對全球醫療保健需求挑戰做出了重大貢獻。 不斷增長的老年人口和迅速增加的慢性病發病率正在迅速增加全球醫療保健成本。 HIFU 對醫療保健公司和付款人來說是一種有吸引力的應對措施,提供具有成本效益的微創幹預措施。 在不斷累積的科學證據的支持下,人們對 HIFU 益處的認識不斷提高,刺激了患者和醫療保健專業人員的需求增加,推動了 HIFU 治療市場的成長。
此外,HIFU 處於臨床創新的前沿,有望改變疾病治療策略。 HIFU利用高頻聲波精確聚焦特定組織,為傳統手術和放射治療提供了微創、定期的治療機會。 技術進步正在推動這一領域的發展,提供改進的即時影像處理、提高瞄準精度的機器人結構以及允許更深層組織穿透的現代感測器設計。 先進的軟體程式協助制定治療計劃,而人工智慧 (AI) 則探索客製化優化。 HIFU 正在擴展到癌症以外的領域,並在臨床證據支持的各種應用中顯示出前景。 新興趨勢包括閉環結構、聯合療法和設備小型化的潛力,將 HIFU 定位為主流替代療法,並為先進的患者護理和結果提供持續有趣的創新。 因此,2023年HIFU治療市場估值為11,555萬美元。
從技術上看HIFU治療市場,MRI HIFU治療這種將MRI引導無縫整合到HIFU流程的創新技術,正在推動全球HIFU市場的大幅成長。 研究表明,MRI HIFU 具有更高的成功率和更少的頭痛,尤其是在複雜的病例中,仍然是微創的,並且具有較低的恢復時間和住院率。 其高精度已將其應用範圍擴展到多種疾病,包括前列腺癌、肝臟腫瘤、子宮肌瘤和嚴重震顫。
從應用來看,世界上最常見的癌症前列腺癌正在推動對 HIFU 的需求。 HIFU 的非手術優勢是癒合更快和出血最少,這使其對尋求微創選擇的人很有吸引力。 它在初步、搶救和安寧療護方面的多功能性擴展了其用途。 技術進步,尤其是即時影像處理和能量傳輸方面的技術進步,將提高準確性、有效性和安全性,確保 HIFU 保持競爭力。 患者和醫療保健專業人員日益關注將推動市場需求,而認識到 HIFU 潛力並批准新應用的支持性監管環境將推動擴張並促進創新。
對於最終用戶來說,醫院可以透過專用的治療設施、訓練有素的員工、卓越的影像處理和強大的基礎設施,將HIFU 無縫地結合到泌尿科、腫瘤科和疼痛控制等醫學專業中。 醫院充當轉診中心,指導患者接受 HIFU 治療並創造有吸引力的患者。 醫院的金融資產支持對 HIFU 設備進行全面投資,確保持續的訪問。 領先的醫院正在積極為 HIFU 研究做出貢獻,促進創新並改進治療方案。 此外,其在監管合規、保護協議和賠償談判中的作用鞏固了其在全球 HIFU 市場的主導地位。
按國家劃分,在美國,早期的貢獻和持續的改進增強了製造商的實力,FDA 強大的監管框架增強了信心並促進了 HIFU 在醫療保健系統中的採用。 美國的高護理率鼓勵醫院迅速採用最新技術。 政府的重大研究和基礎設施的改善正在推動 HIFU 的創新並吸引投資和人才。
本報告分析了全球HIFU(高強度聚焦超音波)市場,提供了市場基本結構、主要市場促進和限制因素、整體市場規模趨勢以及細分/區域趨勢等資訊。我們正在調查其他詳細趨勢、主要公司概況及業績趨勢等。
High-intensity targeted ultrasound therapy market is anticipated to be worth around US$ 194.18 Million by 2030, as according to Renub Research. High-Intensity Focused Ultrasound (HIFU) therapy is a modern-day scientific approach gaining prominence for its non-invasive method. HIFU objectives specific tissues with the aid of using particular ultrasound waves, generating heat for therapeutic applications without damaging surrounding areas. Widely used for situations like prostate cancer and uterine fibroids, HIFU minimizes healing instances and side effects compared to standard medications. Its reputation stems from its precision, decreased invasiveness, and capability programs in various medical fields. As demand for non-surgical interventions rises, HIFU emerges as a transformative technology, using advancements within the clinical panorama with its effectiveness and minimum impact on patients.
Cancer rates are disproportionately excessive in developing nations, affecting about One in Three people all through their lifetime, as per the Global Burden of Diseases (GBD). Uterine fibroids, 77% of ladies of age 50, contribute notably to global healthcare demanding challenges, with an expected 226.05 Million cases. The growing elderly populace and the surge in chronic diseases are escalating global healthcare expenditure. High-Intensity Focused Ultrasound (HIFU) is an attractive response for healthcare companies and payers, offering cost effectiveness and minimally invasive interventions. The increasing cognizance of HIFU's benefits, supported by mounting scientific proof, drives increasing demand among patients and healthcare professionals, propelling the HIFU therapy market increase.
Further, High-depth, focused ultrasound stands at the forefront of clinical innovation, poised to transform disease treatment tactics. Precisely concentrating on particular tissues with high-frequency sound waves, HIFU provides a minimally invasive and regularly curative opportunity to conventional surgery and radiation therapy. Technological strides propel the sector's increase, providing real-time imaging improvements, robot structures improving targeting accuracy, and modern transducer designs allowing deeper tissue penetration. Advanced software programs aid treatment planning, while A.I. explores customized optimization. Expanding beyond cancer, HIFU shows promise in diverse applications sponsored by developing clinical evidence. Emerging trends include closed-loop structures, combination therapies, and the potential miniaturization of gadgets, positioning HIFU as a mainstream healing alternative with ongoing interesting innovations for advanced patient care and results. Hence, the High-Intensity Focused Ultrasound Therapy Market was valued at US$ 115.55 Million in 2023.
Besides, regulatory approvals are pivotal for HIFU technology, boosting credibility and spurring investor confidence, prompting improved investment in research, improvement, and commercialization. Beyond confidence-building, approvals broaden HIFU's market reach by endorsing new applications, tapping into untapped patient populations, diversifying treatments, and adding revenue streams. Examples encompass U.S. Food and Drug Administration (FDA) approvals for chronic tremor, prostate cancer, uterine fibroids, and persistent pain, European Medicines Agency (EMA) acclaim for uterine fibroids, and Chinese Food and Drug Administration (CFDA) approval for liver cancer, pancreatic cancer, and bone tumors. The HIFU market's expansion into aesthetic applications, like skin tightening and fat removal, similarly propels usual growth.
The high-intensity focused ultrasound therapy market is divided into ultrasound HIFU therapy and MRI HIFU therapy by imaging technology. This innovative technique seamlessly integrates MRI steering into the HIFU process, driving a sizeable increase in the global HIFU market. Studies indicate advanced success rates and lower headaches for MRI HIFU, especially in complicated cases, preserving its minimally invasive nature and lowering restoration times and hospitalization rates. Its precision expands applications across numerous conditions like prostate cancer, liver tumors, uterine fibroids, and critical tremors.
Continuous technological improvements in MRI and HIFU transducers shape the market's trajectory, enhancing accuracy and efficacy. Mounting clinical evidence supports the protection and effectiveness of MRI HIFU, fostering wider adoption by healthcare providers. Increased focus has precipitated heightened funding, contributing to the ongoing growth and promising future outlook of the MRI HIFU market.
By application, the High-Intensity Focused Ultrasound Therapy Market is fragmented into Prostate Cancer, Uterine Fibroids, Neurological Disorders, Aesthetics, and Others. Prostate cancer, the most common cancer globally, drives the demand for HIFU (high-depth focused ultrasound) due to its minimally invasive technique, proven efficacy in early-level cases, and non-surgical benefits for faster healing. HIFU's non-surgical benefits, which include more rapid healing and minimal blood loss, appeal to those seeking minimum invasive options. Its versatility in preliminary remedy, salvage therapy, and palliation widens its utility. Technological improvements, especially in real-time imaging and energy delivery, enhance accuracy, efficacy, and safety, ensuring HIFU stays competitive. Increasing attention amongst patients and healthcare professionals drives market demand, while a supportive regulatory environment, spotting HIFU's potential and approving new applications, propels expansion and fosters innovation.
By end-user, the High-Intensity Focused Ultrasound Therapy Market is broken up into Diagnostic Centers, Hospitals, Research Centers, and Others. Hospitals seamlessly combine HIFU into their medical specialties, consisting of urology, oncology, and pain control, possessing dedicated remedy facilities, trained employees, superior imaging, and sturdy infrastructure. Hospitals channel patients to HIFU remedies as referral centers, creating a captive audience. Their monetary assets permit full-size investments in HIFU devices, ensuring consistent access. Leading hospitals actively contribute to HIFU research, fostering innovation and improving therapy protocols. Also, their regulatory compliance, protection protocols, and role in compensation negotiations solidify their dominance in steering the global HIFU market.
By country, the High-Intensity Focused Ultrasound Therapy Market is categorized into United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa and Rest of World. Early contributions and ongoing improvements bolster U.S. producers, with the FDA's sturdy regulatory framework instilling self-assurance and promoting widespread HIFU adoption in the healthcare system. High U.S. healthcare rates facilitate the speedy adoption of modern-day technologies by hospitals. The state's vital research and improved infrastructure drives HIFU innovation, attracting investment and talent.
Aligned with the healthcare system's preference for minimally invasive methods, HIFU's non-surgical technique fits situations like prostate cancer and uterine fibroids. Growing public focus, fuelled by media and advocacy, propels HIFU demand, encouraging healthcare companies to combine it prominently. The favorable repayment panorama incentivizes hospitals and vendors to embody HIFU readily.
Koninklijke Philips N.V., Johnson & Johnson, Hitachi Ltd., General Electrics, Medtronic Plc., Stryker, EDAP TMS S.A, and Theraclion are prominent players in the High Intensity Focused Ultrasound Therapy Market.
Renub Research report titled "High Intensity Focused Ultrasound Therapy Market Forecast by imaging technology (Ultrasound HIFU Therapy, and MRI HIFU Therapy), application (Prostate Cancer, Uterine Fibroids, Neurological Disorders, Aesthetics, and Others), end-user (Diagnostic Centers, Hospitals, Research Centers, and Others), country (United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, Turkey, China, Japan, India, South Korea, Thailand, Malaysia, Indonesia, Australia, New Zealand, Brazil, Mexico, Argentina, Saudi Arabia, UAE, South Africa, and Rest of the World), company (Koninklijke Philips N.V., Johnson & Johnson, Hitachi Ltd., General Electrics, Medtronic Plc., Stryker, EDAP TMS S.A, and Theraclion)" provides a detailed and comprehensive insight of the High Intensity Focused Ultrasound Therapy Industry.